In a keynote session at CPHI North America, Stephanie Gaulding, executive director of regulatory compliance at Pharmatech Associates, calls for innovators to look closely at the frameworks they agree to and work to mitigate future challenges.
Noel Maestre, PE, vice president of Life Sciences, and David Estape, technology manager Biotechnology at CRB discuss how virus response rewrote the playbook for vaccine response, but even more change is necessary to deal with emerging threats.
For pharmaceuticals manufacturers, progressing digitalisation and moving to the cloud has been notoriously slow, and misperceptions of what moving to the cloud entails have been a significant factor in this lack of adoption.
Polling conducted across six European countries, with over 6,000 respondents, finds high levels of excitement for gene therapy and medical innovation, particularly for the treatment of rare diseases.
Dave Walsha, sales manager at precision drive system supplier, Electrical Mechanical Systems (EMS), explores how micromotors are helping drug discovery.
Justin Wilson, partner and attorney at Withers & Rodgers, discusses his opinion on the promising innovations in the microbiome and the role of IP in supporting the discovery of new drugs and treatments.
We know disease exists, where it comes from and how it evolves - but we don’t yet know ahead of time when something changes to mark the start of a new disease, a new variant or just an increase in transmission.
Paul O’Donohoe - senior director of eCOA Product and Science at Medidata, a Dassault Systèmes company, explains how decentralised clinical trials came to be during the Covid-19 pandemic.
